Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Mol Cancer Res. 2021 Oct 11;20(1):45–55. doi: 10.1158/1541-7786.MCR-21-0442

Figure 3.

Figure 3.

Frequency of genetic alterations linked to BRAF inhibitor resistance and/or anaplastic thyroid cancer pathogenesis for tumors that dedifferentiated after vemurafenib or dabrafenib (MSK-THY2-7) compared to those that did not dedifferentiate (MSK-THY8-16). Filled in squares represent mutated genes, with the exception of MET amp, indicating amplification. Pre: before BRAF inhibition, Post: during or after BRAF inhibition, PTC: Papillary Thyroid Cancer, PDTC: Poorly Differentiated Thyroid Cancer, ATC: Anaplastic Thyroid Cancer